In November 2026, Marsh reported that the average total cost of US employer-sponsored health benefits reached USD 18,777 per employee in its final 2026 survey, an increase of 7.3%. The results were announced on 17 November and cover the 2026 plan year. The same survey puts expected growth in 2027 at 8.2%. That second number is a projection from employers, not a renewal outcome already agreed across the market.
The survey provides a reference point for a multinational budget, but it cannot replace a local explanation of the increase. A rise in the cost per employee can reflect a more expensive mix of claims, higher prices for individual services, or changes in the mix of employees and dependants covered. It may also reflect a richer benefit.
Separate plan spending from employee affordability
Marsh compares the 7.3% reported increase with an estimated 9% increase before employers made changes. Treat the gap as a useful indicator of the choices employers made, rather than a controlled estimate of the impact of any one initiative. The average deductible in large employers’ preferred provider organisation plans rose by about 10%, according to the survey. Raising a deductible can reduce what a plan pays while leaving employees to bear more expense when they need care.
For a board or compensation committee, it helps to see three figures side by side: employer spending, worker premium contributions and what participants pay when they use care. Averages can conceal the effect on lower paid employees and on families with recurring prescriptions or specialist visits. Ask for examples at different wage levels and for different coverage tiers. Where an employer changes the network, include an assessment of whether participants still have practical access to providers, including outside the main office locations.
Ask which cost controls are working
Marsh points to several pressures, including claims disputes, use of GLP-1 medicines and changes in provider billing. These are starting points for questions about the plan’s own experience; the national results cannot establish how much each factor contributed at an individual employer. A finance team can ask its administrator to split the growth in paid claims into unit cost, use of care and changes in the mix of care. A separate analysis of large cases and late developments helps show how much of the increase is likely to persist.
Specialised care or a narrower provider network should also come with a measurable objective. A programme intended to improve access needs a baseline for appointment times and completion of referrals. A programme intended to lower spending should account for vendor fees and for claims incurred outside the programme. Employers should agree these measures before renewal, when they still have a choice between bids and enough time to communicate a change to their workforce.
Use comparable assumptions at renewal
Set a baseline using the same enrolment, benefit design and accounting period before comparing competing offers. Ask carriers to distinguish agreed rates from illustrative trends and to explain how network changes affect both expected claims and member access. For self-funded plans, also show the effect of any change in stop-loss attachment points, exclusions or retained exposure. A lower quoted premium can come with a higher amount of risk left on the employer’s balance sheet.
It also helps to set decision thresholds in advance. A company might accept a modest increase in employer cost to prevent a large deterioration in affordability for its lowest-paid employees. Document that trade-off explicitly so procurement, finance and HR are judging alternatives against the same objective.
For a global benefits team, the value of this release is a sharper set of questions for US renewals. Start from the 2026 experience, make the 2027 assumptions explicit and show how each lever affects the employer and the employee. If a savings claim cannot be tied to a change in price, use of care, benefit design or risk retained, it is not yet a reliable number for the budget.
Sources
Mercer / Marsh: final survey analysis
Source: 2026-11-18_GBV_Marsh_US_Health_Benefit_Costs.docx
